Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 368


Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.

Vermont CL, van Dijken HH, van Limpt CJ, de Groot R, van Alphen L, van Den Dobbelsteen GP.

Infect Immun. 2002 Feb;70(2):584-90.


Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine.

de Kleijn E, van Eijndhoven L, Vermont C, Kuipers B, van Dijken H, Rümke H, de Groot R, van Alphen L, van den Dobbelsteen G.

Vaccine. 2001 Nov 12;20(3-4):352-8.


PorA-specific differences in antibody avidity after vaccination with a hexavalent Men B outer membrane vesicle vaccine in toddlers and school children.

Vermont CL, Van Dijken HH, De Groot R, Van Alphen L, Van Den Dobbelsteen GP.

Vaccine. 2004 Aug 13;22(23-24):3008-13.


Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants.

Ruijne N, Lea RA, O'Hallahan J, Oster P, Martin D.

Clin Vaccine Immunol. 2006 Jul;13(7):797-801.


IgG subclass antibodies to serogroup B meningococcal outer membrane antigens following infection and vaccination.

Sjursen H, Wedege E, Rosenqvist E, Naess A, Halstensen A, Matre R, Solberg CO.

APMIS. 1990 Dec;98(12):1061-9.


Porin A-specific antibody avidity in patients who are convalescing from meningococcal B disease.

Vermont CL, van Dijken HH, de Groot R, van den Dobbelsteen GP.

Pediatr Res. 2005 Jul;58(1):149-52. Epub 2005 Mar 17.


Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.

Vermont CL, van Dijken HH, Kuipers AJ, van Limpt CJ, Keijzers WC, van der Ende A, de Groot R, van Alphen L, van den Dobbelsteen GP.

Infect Immun. 2003 Apr;71(4):1650-5.


Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.

Wedege E, Bolstad K, Aase A, Herstad TK, McCallum L, Rosenqvist E, Oster P, Martin D.

Clin Vaccine Immunol. 2007 Jul;14(7):830-8. Epub 2007 May 9.


Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.

Gorringe AR, Taylor S, Brookes C, Matheson M, Finney M, Kerr M, Hudson M, Findlow J, Borrow R, Andrews N, Kafatos G, Evans CM, Read RC.

Clin Vaccine Immunol. 2009 Aug;16(8):1113-20. doi: 10.1128/CVI.00118-09. Epub 2009 Jun 24.


A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses.

Granoff DM, Maslanka SE, Carlone GM, Plikaytis BD, Santos GF, Mokatrin A, Raff HV.

Clin Diagn Lab Immunol. 1998 Jul;5(4):479-85.


Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies.

Rosenqvist E, Høiby EA, Bjune G, Bryn K, Closs O, Feiring B, Klem A, Nøkleby H, Frølm LO.

NIPH Ann. 1991 Dec;14(2):169-79; discussion 180-1.


Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine.

Naess LM, Oftung F, Aase A, Wetzler LM, Sandin R, Michaelsen TE.

Infect Immun. 1998 Mar;66(3):959-65.


Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine.

Katial RK, Brandt BL, Moran EE, Marks S, Agnello V, Zollinger WD.

Infect Immun. 2002 Feb;70(2):702-7.


Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine.

Oftung F, Naess LM, Wetzler LM, Korsvold GE, Aase A, Høiby EA, Dalseg R, Holst J, Michaelsen TE, Haneberg B.

Infect Immun. 1999 Feb;67(2):921-7.


Differential capacities of outer membrane proteins from Neisseria meningitidis B to prime the murine immune system after vaccination.

Silva Junior FC, Gioia CA, Oliveira JM, Cruz SC, Frasch CE, Milagres LG.

Scand J Immunol. 2007 Jan;65(1):1-7.


Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children.

McVernon J, Maclennan J, Buttery J, Oster P, Danzig L, Moxon ER.

Pediatr Infect Dis J. 2002 Aug;21(8):747-53.


Supplemental Content

Support Center